Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Source · https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-acceptance-of-manuscript-highlighting-utrophin-modulation-potential-of-z-endoxifen-in-duchenne-muscular-dystrophy-302778088.html

Read source

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Search tags

What matters in this story

Atossa Therapeutics' (Z)-endoxifen has received Orphan Drug and Rare Pediatric Disease (RPD) designations from the FDA for the treatment of Duchenne Muscular Dystrophy (DMD). — RPD designation provides a pathway to a Priority Review Voucher (PRV), which has significant independent cash value ($100M-$205M) if sold.

+0.60

A manuscript detailing the potential of (Z)-endoxifen to modulate utrophin pathways in DMD has been accepted for publication in 'Degenerative Neurological and Neuromuscular Disease'. — Peer-reviewed publication provides scientific validation of the mechanism of action, reducing perceived technical risk for the pipeline.

+0.30

The company has identified next steps for (Z)-endoxifen in DMD, including preclinical evaluation in dystrophin-deficient models and biomarker development. — Defines the transition from theoretical/transcriptomic research to actionable preclinical testing, though results are not yet available.

+0.20

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

What matters in this story

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

What matters in this story

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Sentiment in this article

Relationships in this article